FUSID TEVA 20 MG 2 ML

Ország: Izrael

Nyelv: angol

Forrás: Ministry of Health

Aktív összetevők:

FUROSEMIDE

Beszerezhető a:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

ATC-kód:

C03CA01

Gyógyszerészeti forma:

SOLUTION FOR INJECTION / INFUSION

Összetétel:

FUROSEMIDE 20 MG / 2 ML

Az alkalmazás módja:

I.V, I.M

Recept típusa:

Required

Gyártó:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Terápiás terület:

FUROSEMIDE

Terápiás javallatok:

Fusid Teva 20 mg / 2 ml is a potent diuretic indicated for use when a prompt and effective diuresis is required.Fusid Teva 20 mg / 2 ml is appropriate for use in emergencies or where oral therapy is not feasible.The indications include cardiac, pulmonary, hepatic and renal oedema.

Engedély dátuma:

2017-06-08

Termékjellemzők

This leaflet format has been determined by the
Ministry of Health and the content thereof has been
checked and approved
FUSID
® TEVA 20 MG/2 ML
SOLUTION FOR INJECTION OR INFUSION, I.M. / I.V.
1.
NAME OF THE MEDICINAL PRODUCT
Fusid Teva 20 mg/2 ml
2.
QUALITATIVE AND QUANTITATIVE
COMPOSITION
Each ml contains 10 mg of furosemide.
Each 2 ml ampoule contains 20 mg of furosemide.
Sodium content: about 7.3 mg per ampoule of 2 ml.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection or infusion
Clear, colorless to almost colorless solution.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Fusid Teva 20 mg/2 ml is a potent diuretic indicated for
use when a prompt and effective diuresis is required. Fusid
Teva 20 mg/2 ml is appropriate for use in emergencies
or when oral therapy is not feasible. Indications include
cardiac, pulmonary, hepatic and renal oedema.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration: intramuscular or intravenous
use.
Adults
Intravenous furosemide must be injected or infused
slowly; a rate of 4 mg per minute must not be exceeded. In
patients with severe impairment of renal function (serum
creatinine > 5 mg/dl), it is recommended that an infusion
rate of 2.5 mg per minute is not exceeded.
Intramuscular administration must be restricted to
exceptional cases where neither oral nor intravenous
administration is feasible. It must be noted that
intramuscular injection is not suitable for the treatment
of acute conditions such as pulmonary oedema.
To achieve optimum efficacy and suppress counter-
regulation, a continuous furosemide infusion is generally
to be preferred to repeated bolus injections. Where
continuous furosemide infusion is not feasible for follow-
up treatment after one or several acute bolus doses, a
follow-up regimen with low doses given at short intervals
(approximately four hours) is to be preferred to a regimen
with higher bolus doses at longer intervals.
Doses of 20 to 50 mg intramuscularly or intravenously
may be given ini